Close Menu

This article has been updated to include a statement from the Broad Institute.

NEW YORK (GenomeWeb) – CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics said Tuesday that the co-owners of intellectual property relating to CRISPR-Cas9 gene editing technology and licensed by these firms are seeking reversal of a decision by the US Patent and Trademark Office's Patent Trial and Appeal Board in a patent interference proceeding. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.